Ocular Symptoms of Myasthenia Gravis Improved With Rozanolixizumab
Dystrophin Expressing Chimeric Cell Therapy Demonstrates Long-Term Safety in Non-Ambulatory Duchenne Muscular Dystrophy
Baseline Characteristics and Updates for Phase 3 FORTIFY Study of BBP-418 in LGMD
Eteplirsen Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy
